CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
Go back to CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder| CalAmp Corp. (NASDAQ: CAMP) | Delayed: 4.25 -0.09 (2.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.34 | 52 Week High | $21.34 | |||
| Open | $4.46 | 52 Week Low | $12.13 | |||
| Day High | $4.54 | P/E | 3.20 | |||
| Day Low | $4.21 | EPS | $1.33 | |||
| Volume | 101,147 | |||||
